Nanoshells on polymers

Patent metadata

Field	Value
Publication number	US-9439869-B2
Application number	US-201314086907-A
Country	US
Kind code	B2
Filing date	Nov 21, 2013
Priority date	Jun 23, 2006
Publication date	Sep 13, 2016
Grant date	Sep 13, 2016

Abstract

Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.

First claim

We claim:

1. A nano-construct comprising:
(a) a core material comprising a bioactive agent and a poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) tri-block copolymer surfactant, and
(b) a nanoshell formed around the core material,
wherein the nano-construct is modified by attachment of phosphoryl choline, dextran, dextrose, albumin, or any combination thereof to the exterior surface of the nano-construct.

2. The nano-construct of claim 1 , wherein the nanoshell comprises calcium.

3. The nano-construct of claim 2 , wherein the nanoshell further comprises poly(L-lactide), polyhydroxyalkanoate, polycaprolactone, or a combination thereof.

4. The nano-construct of claim 1 , wherein the nanoshell has a thickness between about 5 and about 25 nm.

5. The nano-construct of claim 1 , wherein the nanoshell surrounding the core material is porous to the bioactive agent, and wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, 4-amino-2,2,6,6-tetramethylpiperidine-l-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)-ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), hirudin, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, and combinations thereof.

6. The nano-construct of claim 1 , wherein the core material has a size in the range between about 150 nm to about 2000 nm.

7. The nano-construct of the claim 1 , wherein the core material comprises ferromagnetic or magnetic ceramic particles, a peptide, a protein, or a combination thereof; and wherein if a peptide, a protein or a combination of a peptide and a protein is present, the bioactive agent comprises the peptide, the protein, or the combination of the peptide and the protein.

8. The nano-construct of claim 1 , further comprising
a substrate, the substrate being a small unilamellar vesicle (SUV), a liposome, a polymersome, or a hybrid vesicle.

9. The nano-construct of claim 1 , further comprising:
a targeting molecule on the exterior surface of the nano-construct, wherein the targeting molecule is a surface-conjugated ligand for receptors on an inflamed endothelium.

10. A method of treating or ameliorating a medical condition in a human being, comprising:
delivering to a disease site in the body of the human being in need of treatment the nano-construct of claim 1 , wherein the bioactive agent is a therapeutic agent.

11. The method of claim 10 , wherein the disease is selected from the group consisting of tumors, nephropathic kidney, vascular conditions, atherosclerotic plaque, vulnerable plaque, vascular inflammation, diffuse atherosclerotic disease, restenosis, diabetic retinopathy, aneurysm, anastomotic hyperplasia, claudication, chronic total occlusion, dysfunctional endothelium, recurring thrombus, fibrin accumulation, and combinations thereof.

Assignees

• Abbott Cardiovascular Systems Inc
• Abott Cardiovascular Systems Inc

Inventors

• Ludwig Florian N
• Pacetti Stephen D
• Hossainy Syed F A
• Davalian Dariush

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K41/0052

  Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy · CPC title